EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial

Nermin Diab iD, Danica Brister, Elena Kum, Mustafaa Wahab, Wafa Hassan iD, Sue Beaudin, Catie Obminski, Jennifer Wattie, Lesley Wiltshire, Karen Howie, Kieran Killian, Kimberley Holt iD und 5 weitere

European Respiratory Journal · 2026-04 · 67 (4) · 2501573

DOI: 10.1183/13993003.01573-2025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, online erschienen am 06.11.2025. Verfasst von Nermin Diab und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Research Institute of the McGill University Health System, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cough, Eosinophilia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: investigator-initiated grant from GlaxoSmithKline to McMaster University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients presenting with chronic cough often have eosinophilic airways disease that remains refractory despite inhaled or oral corticosteroids. Studies in asthma patients have shown that eosinophils co-localise with airway sensory nerves, and after allergen challenge, are associated with neuronal sensitivity. We evaluated whether mepolizumab, a monoclonal antibody targeting interleukin-5, reduces cough in patients with eosinophilic airways disease.

Methods

We conducted a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial of 30 patients with refractory chronic cough and eosinophilic airways disease (sputum eosinophils ≥2%). Patients underwent 1:1 randomisation to receive subcutaneous mepolizumab (100 mg) or placebo every 4 weeks for 12 weeks. Change from baseline in 24-h cough frequency at 14 weeks represented the primary end-point. Measurements and main results Compared to placebo, mepolizumab did not lead to improvements in 24-h cough frequency at 14 weeks (percentage change relative to placebo +18.0%, 95% CI −46.4–160.1%; p=0.99). We found no between-group differences in awake cough frequency, sleep cough frequency, cough severity on the 100-mm visual analogue scale, and quality of life on the Leicester Cough Questionnaire. Mepolizumab significantly reduced blood eosinophils compared to placebo at week 14 (mean difference −237.7 cells·µL −1 , 95% CI −328.3–−147.1 cells·µL −1 ; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCoughEosinophiliaHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultChronic DiseaseEosinophilsTreatment OutcomeAgedInterleukin-5SputumQuality of LifeAsthmaChronic Cough

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedInterleukin-5

Autor:innen und Institutionen

  • Department of Medicine and Research Institute of the McGill University Health System, McGill University, Montreal, QC, Canada.
  • Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
  • Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, ON, Canada.
  • Department of Medicine, McMaster University, Hamilton, ON, Canada satiai@mcmaster.ca.

ORCID-Profile: Nermin Diab, Wafa Hassan, Kimberley Holt, Roma Sehmi, Gail M Gauvreau, Jaclyn A Smith, Paul M O'Byrne, Imran Satia

Förderung

  • investigator-initiated grant from GlaxoSmithKline to McMaster University

Zitieren

APA

Diab, N., Brister, D., Kum, E., Wahab, M., Hassan, W., Beaudin, S., Obminski, C., Wattie, J., Wiltshire, L., Howie, K., Killian, K., Holt, K., Sehmi, R., Gauvreau, G. M., Smith, J. A., O'Byrne, P. M., & Satia, I. (2026). Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial. European Respiratory Journal, 67(4), 2501573. https://doi.org/10.1183/13993003.01573-2025

Vancouver

Diab N, Brister D, Kum E, Wahab M, Hassan W, Beaudin S, et al. Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial. European Respiratory Journal. 2026;67(4):2501573. doi:10.1183/13993003.01573-2025

BibTeX
@article{Diab2026,
  author = {Diab, Nermin and Brister, Danica and Kum, Elena and Wahab, Mustafaa and Hassan, Wafa and Beaudin, Sue and Obminski, Catie and Wattie, Jennifer and Wiltshire, Lesley and Howie, Karen and Killian, Kieran and Holt, Kimberley and Sehmi, Roma and Gauvreau, Gail M and Smith, Jaclyn A and O'Byrne, Paul M and Satia, Imran},
  title = {Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial},
  journal = {European Respiratory Journal},
  year = {2026},
  volume = {67},
  number = {4},
  pages = {2501573},
  doi = {10.1183/13993003.01573-2025}
}
Kostenlos starten →